
AMC exits Optimapharm
CEE-focused Mezzanine Management has fully exited its investment in European contract research organisation Optimapharm by selling it to The Rohatyn Group. Mezzanine Management is an advisor to the AMC group of funds, whose total investments exceed EUR700 million. The investment advisory firm has been operating in Central Europe since 2000 from


